重药控股股份有限公司发布股份回购进展公告，累计回购金额超8000万元

2026年5月7日，重药控股股份有限公司（证券代码：000950，证券简称：重药控股）发布了关于公司股份回购进展的最新公告。

关键要点：

• 回购方案获批：公司已于2025年7月10日及7月28日分别召开董事会和股东大会，审议并通过了《关于回购公司股份的议案》。本次回购资金来源为自有资金及股票回购专项贷款。
• 回购目的：本次回购股份将用于减少公司注册资本，属于注销回购。
• 回购资金及价格区间：本次回购资金总额不低于人民币8000万元，不超过人民币1亿元。回购价格不超过6.6元/股。
• 回购期限：自股东大会审议通过事项之日起12个月内。
• 最新回购进展：截至2026年4月30日，公司通过集中竞价交易方式累计回购15,406,600股，约占公司总股本的0.8915%。最高成交价为5.48元/股，最低成交价为5.01元/股，累计支付总金额为80,998,765.98元（不含交易费用）。
• 合规性声明：公司回购操作严格遵守了《上市公司股份回购规则》及深圳证券交易所相关自律监管指引的规定。

对投资者的影响与需关注事项：

• 股份回购用于注销：本次回购股份将用于减少公司注册资本，对二级市场流通股本形成收缩，有望提升每股收益与投资价值，对股价存在正面影响。
• 回购价格区间与进展：回购价格上限为6.6元/股，实际成交区间为5.01~5.48元/股，表明公司认为目前股价被低估，管理层对公司未来发展有信心。
• 回购金额已达下限：目前累计回购金额已达公告下限（8000万元），但距离上限（1亿元）尚有空间，后续仍可能继续回购，值得投资者持续关注。
• 严格信息披露与合规操作：公司未在敏感期、重大事项未披露期间进行回购，严格遵守监管部门相关要求，有利于维护投资者利益和市场公平。
• 后续计划：公司将根据市场情况在回购期限内继续实施回购，并及时披露相关进展，请投资者注意相关信息更新及市场风险。

潜在影响及投资者关注点：

此次大额股份回购并用于注销，将直接影响公司流通股本及每股收益等核心财务指标，或对公司股价形成支撑和提振。投资者需关注公司后续回购进展及市场表现，同时结合行业与公司基本面做出理性判断。

免责声明：本文仅供参考，不构成投资建议。股市有风险，投资需谨慎。请投资者结合自身实际情况及风险承受能力，理性决策。

English Version

Chongyao Holdings Co., Ltd. Announces Progress in Share Buyback, Repurchasing Over 80 Million Yuan

On May 7, 2026, Chongyao Holdings Co., Ltd. (Stock Code: 000950, Stock Abbreviation: Chongyao Holdings) released the latest announcement on the progress of its share buyback program.

Key Highlights:

• Buyback Plan Approved: The company held board and shareholder meetings on July 10 and July 28, 2025, approving the share buyback plan. The buyback will use both internal funds and special buyback loans.
• Purpose of Buyback: The repurchased shares will be used to reduce the company’s registered capital, i.e., they will be cancelled.
• Buyback Amount and Price Range: The total funds for the buyback will be no less than RMB 80 million and no more than RMB 100 million. The buyback price will not exceed RMB 6.6 per share.
• Buyback Period: Within 12 months from the date the buyback was approved by the shareholders’ meeting.
• Latest Progress: As of April 30, 2026, the company has repurchased a total of 15,406,600 shares through centralized bidding, accounting for about 0.8915% of total share capital. The highest transaction price was RMB 5.48 per share, the lowest was RMB 5.01 per share, with a total payment of RMB 80,998,765.98 (excluding transaction fees).
• Compliance Statement: The buyback strictly adheres to the relevant rules and regulatory guidelines of the Shenzhen Stock Exchange.

Investor Impact and Points to Note:

• Buyback for Cancellation: The repurchased shares will be cancelled, reducing the company’s registered capital and circulating shares, which may enhance EPS and investment value, potentially supporting the share price.
• Buyback Price Range and Progress: The maximum buyback price is RMB 6.6 per share, with actual transactions between RMB 5.01 and RMB 5.48 per share, indicating management sees the stock as undervalued and is confident in the company’s prospects.
• Buyback Amount Reaches Minimum: The current repurchase amount has reached the minimum threshold (RMB 80 million) but is below the maximum (RMB 100 million), so further buybacks may occur. Investors should continue to monitor progress.
• Strict Disclosure and Compliance: The company has not conducted buybacks during sensitive periods or before major events are disclosed, strictly following regulatory requirements, which protects investor interests and ensures market fairness.
• Future Plans: The company will continue to implement the buyback plan within the approved period based on market conditions and will disclose progress in a timely manner. Investors should pay attention to follow-up announcements and market risks.

Potential Impact and Investor Focus:

This significant buyback and cancellation will directly impact the company’s circulating share capital and key financial indicators such as EPS, potentially supporting and boosting the share price. Investors should monitor ongoing buyback progress, company fundamentals, and industry trends for informed decision-making.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Stock market investments carry risks. Please make decisions prudently based on your own risk tolerance and circumstances.

View 重药控股 Historical chart here